Have a feature idea you'd love to see implemented?
Let us know!
LPCN Lipocine Inc
Price (delayed)
$5.0001
Market cap
$26.74M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.74
Enterprise value
$23M
Lipocine Inc. is a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders using its proprietary drug delivery technologies. Lipocine's clinical development pipeline includes: TLANDO, LPCN 1144, TLANDO XR, LPCN
Highlights
Lipocine's EPS has surged by 76% YoY and by 53% QoQ
LPCN's net income has soared by 75% YoY and by 52% QoQ
Lipocine's equity has decreased by 15% YoY and by 10% QoQ
Key stats
What are the main financial stats of LPCN
Market
Valuations
Earnings
Shares outstanding
5.35M
Market cap
$26.74M
Enterprise value
$23M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.4
Price to sales (P/S)
3.38
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.9
Revenue
$7.92M
EBIT
-$4.05M
EBITDA
-$4.02M
Free cash flow
-$5.03M
Per share
Balance sheet
Liquidity
EPS
-$0.74
Free cash flow per share
-$0.94
Book value per share
$3.57
Revenue per share
$1.48
TBVPS
$3.87
Total assets
$20.7M
Total liabilities
$1.58M
Debt
$0
Equity
$19.12M
Working capital
$18.92M
Debt to equity
0
Current ratio
12.97
Quick ratio
12.54
Net debt/EBITDA
0.93
Margins
Efficiency
Dividend
EBITDA margin
-50.8%
Gross margin
100%
Net margin
-51.2%
Operating margin
-66.8%
Return on assets
-17.6%
Return on equity
-19.2%
Return on invested capital
-24%
Return on capital employed
-21.2%
Return on sales
-51.2%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
LPCN stock price
How has the Lipocine stock price performed over time
Intraday
6.16%
1 week
-4.03%
1 month
-10.07%
1 year
99.21%
YTD
79.22%
QTD
11.36%
Financial performance
How have Lipocine's revenue and profit performed over time
Revenue
$7.92M
Gross profit
$7.92M
Operating income
-$5.29M
Net income
-$4.06M
Gross margin
100%
Net margin
-51.2%
LPCN's net income has soared by 75% YoY and by 52% QoQ
LPCN's net margin has surged by 71% since the previous quarter
The company's operating income has surged by 70% YoY and by 45% QoQ
LPCN's operating margin has surged by 67% since the previous quarter
Growth
What is Lipocine's growth rate over time
Valuation
What is Lipocine stock price valuation
P/E
N/A
P/B
1.4
P/S
3.38
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.9
Lipocine's EPS has surged by 76% YoY and by 53% QoQ
The P/B is 42% less than the 5-year quarterly average of 2.4 but 8% more than the last 4 quarters average of 1.3
Lipocine's equity has decreased by 15% YoY and by 10% QoQ
LPCN's revenue has soared by 65% since the previous quarter
Efficiency
How efficient is Lipocine business performance
Lipocine's return on sales has surged by 71% QoQ
LPCN's ROA has soared by 66% year-on-year and by 50% since the previous quarter
Lipocine's ROE has soared by 65% YoY and by 50% from the previous quarter
The ROIC has soared by 62% YoY and by 50% from the previous quarter
Dividends
What is LPCN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for LPCN.
Financial health
How did Lipocine financials performed over time
LPCN's total liabilities is down by 30% year-on-year and by 13% since the previous quarter
The current ratio has grown by 18% YoY and by 3.3% from the previous quarter
LPCN's debt is 100% smaller than its equity
Lipocine's equity has decreased by 15% YoY and by 10% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.